TPI 287, A Taxane Derivative that Crosses the Blood Brain Barrier, for the Treatment of Glioblastoma
- A novel formulation of a taxane (abeotaxane) that effectively crosses the BBB
- Studied in over 350 patients to date, which include positive Phase 1 clinical trials in GBM
- Proposed Phase 2 trial for 2nd line GBM with an additional focus on the exploration of potential biomarkers